682 related articles for article (PubMed ID: 25989706)
21. Bevacizumab treatment for acute branch retinal vein occlusion accompanied by subretinal hemorrhage.
Zhao L; Li B; Feng K; Han L; Ma Z; Liu Y
Curr Eye Res; 2015 Jul; 40(7):752-6. PubMed ID: 25330134
[TBL] [Abstract][Full Text] [Related]
22. Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion.
Jaissle GB; Szurman P; Feltgen N; Spitzer B; Pielen A; Rehak M; Spital G; Heimann H; Meyer CH;
Graefes Arch Clin Exp Ophthalmol; 2011 Feb; 249(2):183-92. PubMed ID: 21337042
[TBL] [Abstract][Full Text] [Related]
23. Predictive factors for recurrence of macular edema after successful intravitreal bevacizumab therapy in branch retinal vein occlusion.
Yamada R; Nishida A; Shimozono M; Kameda T; Miyamoto N; Mandai M; Kurimoto Y
Jpn J Ophthalmol; 2015 Nov; 59(6):389-93. PubMed ID: 26335912
[TBL] [Abstract][Full Text] [Related]
24. Repeated intravitreal bevacizumab injection with and without macular grid photocoagulation for treatment of diffuse diabetic macular edema.
Solaiman KA; Diab MM; Dabour SA
Retina; 2013 Sep; 33(8):1623-9. PubMed ID: 23538584
[TBL] [Abstract][Full Text] [Related]
25. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
Spooner K; Fraser-Bell S; Hong T; Chang A
Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
[TBL] [Abstract][Full Text] [Related]
26. Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes.
Puche N; Glacet A; Mimoun G; Zourdani A; Coscas G; Soubrane G
Acta Ophthalmol; 2012 Jun; 90(4):357-61. PubMed ID: 20602625
[TBL] [Abstract][Full Text] [Related]
27. A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL Report No. 1.
Narayanan R; Panchal B; Das T; Chhablani J; Jalali S; Ali MH;
Br J Ophthalmol; 2015 Jul; 99(7):954-9. PubMed ID: 25631483
[TBL] [Abstract][Full Text] [Related]
28. Macular cystic changes as predictive factor for the recurrence of macular oedema in branch retinal vein occlusion.
Tilgner E; Dalcegio Favretto M; Tuisl M; Wiedemann P; Rehak M
Acta Ophthalmol; 2017 Nov; 95(7):e592-e596. PubMed ID: 28266152
[TBL] [Abstract][Full Text] [Related]
29. Cytokine Kinetics after Monthly Intravitreal Bevacizumab for Retinal Vein Occlusion Associated with Macular Oedema.
Noma H; Mimura T; Yasuda K; Shimura M
Ophthalmic Res; 2016; 56(4):207-214. PubMed ID: 27160159
[TBL] [Abstract][Full Text] [Related]
30. Intravitreal bevacizumab and cytokine levels in major and macular branch retinal vein occlusion.
Lim JW
Ophthalmologica; 2011; 225(3):150-4. PubMed ID: 21150231
[TBL] [Abstract][Full Text] [Related]
31. Changes in retinal blood flow in patients with macular edema secondary to branch retinal vein occlusion before and after intravitreal injection of bevacizumab.
Nagaoka T; Sogawa K; Yoshida A
Retina; 2014 Oct; 34(10):2037-43. PubMed ID: 24896136
[TBL] [Abstract][Full Text] [Related]
32. Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES): six-month results of a prospective randomized clinical trial.
Pielen A; Mirshahi A; Feltgen N; Lorenz K; Korb C; Junker B; Schaefer C; Zwiener I; Hattenbach LO;
Acta Ophthalmol; 2015 Feb; 93(1):e29-37. PubMed ID: 25042729
[TBL] [Abstract][Full Text] [Related]
33. Combination of peripheral laser photocoagulation with intravitreal bevacizumab in naïve eyes with macular edema secondary to CRVO: prospective randomized study.
Chhablani J; Narayanan R; Mathai A; Tyagi M
Eye (Lond); 2016 Jul; 30(7):1025-7. PubMed ID: 27034198
[No Abstract] [Full Text] [Related]
34. Changes of aqueous vascular endothelial growth factor and pigment epithelium-derived factor following intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion.
Park SP; Ahn JK
Clin Exp Ophthalmol; 2009 Jul; 37(5):490-5. PubMed ID: 19624346
[TBL] [Abstract][Full Text] [Related]
35. "Off-label" use of intravitreal bevacizumab in non-ischemic macular edema secondary to retinal vein obstructions.
Dascalu AM; Popa-Cherecheanu A; Popa-Cherecheanu M; Nica A; Serban D
Rom J Ophthalmol; 2016; 60(2):90-95. PubMed ID: 29450329
[TBL] [Abstract][Full Text] [Related]
36. Combination of Ranibizumab with macular laser for macular edema secondary to branch retinal vein occlusion: one-year results from a randomized controlled double-blind trial.
Song S; Yu X; Zhang P; Gu X; Dai H
BMC Ophthalmol; 2020 Jun; 20(1):241. PubMed ID: 32560639
[TBL] [Abstract][Full Text] [Related]
37. Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular edema: results of the Pan-american Collaborative Retina Study Group at 24 months.
Arevalo JF; Lasave AF; Wu L; Diaz-Llopis M; Gallego-Pinazo R; Alezzandrini AA; Berrocal MH;
Retina; 2013 Feb; 33(2):403-13. PubMed ID: 23222389
[TBL] [Abstract][Full Text] [Related]
38. Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion.
Tan MH; McAllister IL; Gillies ME; Verma N; Banerjee G; Smithies LA; Wong WL; Wong TY
Am J Ophthalmol; 2014 Jan; 157(1):237-247.e1. PubMed ID: 24112635
[TBL] [Abstract][Full Text] [Related]
39. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study.
Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
Retina; 2007 Feb; 27(2):141-9. PubMed ID: 17290194
[TBL] [Abstract][Full Text] [Related]
40. Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion.
Russo V; Barone A; Conte E; Prascina F; Stella A; Noci ND
Retina; 2009 Apr; 29(4):511-5. PubMed ID: 19174717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
